Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 466 to 480 of 1238 results for pain

  1. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

  2. Routine preoperative tests for elective surgery (NG45)

    This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.

  3. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

    This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

  4. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

  5. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

  6. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

  7. Percutaneous radiofrequency ablation for renal cancer (HTG226)

    Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.

  8. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (HTG347)

    Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.

  9. VER-01 for treating chronic low back pain [ID6638]

    Awaiting development Reference number: GID-TA11842 Expected publication date: TBC

  10. Prosthetic intervertebral disc replacement in the cervical spine (HTG217)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  11. Balloon cryoablation for Barrett's oesophagus (HTG767)

    Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.

  12. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

  13. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  14. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  15. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .